Immunic, Inc.

IMUX Nasdaq SEC CIK 1280776
Follow Immunic Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$42.3M −65.4% vs same quarter last year
EPS, diluted −$0.99 +25% vs same quarter last year
Operating cash flow −$28.4M −41% vs same quarter last year
Operating income −$43.4M −66.8% vs same quarter last year
Net income by quarter
−$25.2M
−$25.5M
−$26.8M
−$25.6M
−$19.3M
−$32.6M
−$34.1M
−$42.3M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income15 fiscal years
−$150M−$100M−$50M$0FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearNet income
FY25−$97.2M
FY24−$100.5M
FY23−$93.6M
FY22−$120.4M
FY21−$92.9M
FY20−$44M
FY19−$34.9M
FY18−$11.5M
FY17−$52.1M
FY16−$41M
FY15−$52M
FY14−$47.7M
FY13−$32.7M
FY12−$6.7M
FY11-
Free cash flowOperating cash flow minus capital expenditure
−$100M−$75M−$50M−$25M$0FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$86M
FY24−$85M
FY23−$71.2M
FY22−$65.3M
FY21−$83.3M
FY20−$46.3M
FY19−$28.6M
FY18−$9.8M
FY17−$41.1M
FY16−$36.3M
FY15−$52.3M
FY14−$42.2M
FY13−$30.1M
FY12−$9.5M
FY11-